Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers

Inclusion Criteria: * Subjects must have documented negative HIV serology by ELISA and P24 antigen * Subjects must be clinically well males aged between 18 to 60 years. * Fasting blood glucose, total cholesterol and triglycerides within normal limits * Hepatic transaminases (AST and ALT) ≤ 3 × upper limit of normal (ULN) * Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm3; platelets ≥ 50,000/mm3; hemoglobin ≥ 8.0 g/dL) * Serum amylase ≤ 1.5 × ULN * Sexually active males must use condoms during the course of the study * Life expectancy ≥ 1 year * Willing and able to provide informed consent Exclusion Criteria: * Subjects with a waist hip ratio \> 0.97 or BMI \> 28 kg/m2 will be excluded * Acute or chronic hepatitis B infection (determined by positive hepatitis B surface antigen result at the screening visit) * Acute or chronic hepatitis C infection (determined by positive hepatitis C antibody result at the screening visit) * Other metabolic syndrome or disease process in the opinion of the investigator likely to cause marked disturbance in glucose and lipid homeostasis including hypertension. * Receiving on-going therapy with any of the following: * Metabolically active medications * Any lipid-lowering medication * Hormonal agents (oestrogens or androgens) * Glucocorticoids * Beta-blockers * Thiazide diuretics * Thyroid preparations * Psychotropic agents * Anabolic steroids * Megestrol acetate